Gaboxadol also known as 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) is an experimental sleep aid drug developed by Lundbeck and Merck, who reported increased deep sleep without the reinforcing effects of benzodiazepines. Development of Gaboxadol was stopped in March 2007 after concerns regarding safety and efficacy. It acts on the GABA system, but in a seemingly different way from benzodiazepines and other sedatives.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Gaboxadol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Gaboxadol. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Gaboxadol. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Gaboxadol. |
| Hydrocodone | Gaboxadol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Gaboxadol. |
| Magnesium sulfate | The therapeutic efficacy of Gaboxadol can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Gaboxadol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Gaboxadol may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Gaboxadol. |
| Mirtazapine | Gaboxadol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Gaboxadol. |
| Orphenadrine | Gaboxadol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Gaboxadol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Gaboxadol. |
| Pramipexole | Gaboxadol may increase the sedative activities of Pramipexole. |
| Ropinirole | Gaboxadol may increase the sedative activities of Ropinirole. |
| Rotigotine | Gaboxadol may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Gaboxadol. |
| Sodium oxybate | Gaboxadol may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Gaboxadol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Gaboxadol. |
| Thalidomide | Gaboxadol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Gaboxadol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Mefloquine | The therapeutic efficacy of Gaboxadol can be decreased when used in combination with Mefloquine. |
| Mianserin | The therapeutic efficacy of Gaboxadol can be decreased when used in combination with Mianserin. |
| Orlistat | Orlistat can cause a decrease in the absorption of Gaboxadol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Topotecan | Gaboxadol may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Gaboxadol. |
| Tetracosactide | The risk or severity of liver damage can be increased when Tetracosactide is combined with Gaboxadol. |
| Ethanol | Gaboxadol may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Gaboxadol may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Gaboxadol. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Gaboxadol is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Gaboxadol is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Gaboxadol is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Gaboxadol is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Gaboxadol is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Gaboxadol is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Gaboxadol is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Gaboxadol is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Gaboxadol is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Gaboxadol is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Gaboxadol is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Gaboxadol is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Gaboxadol is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Gaboxadol is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Gaboxadol is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Gaboxadol is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Gaboxadol is combined with Alaproclate. |
| Amitriptyline | The risk or severity of CNS depression can be increased when Amitriptyline is combined with Gaboxadol. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Gaboxadol. |
| Imipramine | The risk or severity of CNS depression can be increased when Imipramine is combined with Gaboxadol. |
| Nortriptyline | The risk or severity of CNS depression can be increased when Nortriptyline is combined with Gaboxadol. |
| Amoxapine | The risk or severity of CNS depression can be increased when Amoxapine is combined with Gaboxadol. |
| Propiomazine | The risk or severity of CNS depression can be increased when Propiomazine is combined with Gaboxadol. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Gaboxadol is combined with Cocaine. |
| Quinidine | The therapeutic efficacy of Gaboxadol can be decreased when used in combination with Quinidine. |
| Maprotiline | The risk or severity of CNS depression can be increased when Maprotiline is combined with Gaboxadol. |
| Doxepin | The risk or severity of CNS depression can be increased when Doxepin is combined with Gaboxadol. |
| Desipramine | The risk or severity of CNS depression can be increased when Desipramine is combined with Gaboxadol. |
| Pizotifen | The risk or severity of CNS depression can be increased when Pizotifen is combined with Gaboxadol. |
| Dosulepin | The risk or severity of CNS depression can be increased when Gaboxadol is combined with Dosulepin. |
| Zopiclone | The risk or severity of adverse effects can be increased when Gaboxadol is combined with Zopiclone. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Gaboxadol. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Gaboxadol. |
| Tryptophan | The risk or severity of CNS depression can be increased when Tryptophan is combined with Gaboxadol. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of Gaboxadol. |
| Lorazepam | The risk or severity of CNS depression can be increased when Lorazepam is combined with Gaboxadol. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Gaboxadol. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with Gaboxadol. |
| Reserpine | The risk or severity of CNS depression can be increased when Reserpine is combined with Gaboxadol. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with Gaboxadol. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with Gaboxadol. |
| Temazepam | The risk or severity of CNS depression can be increased when Temazepam is combined with Gaboxadol. |
| Reboxetine | The risk or severity of CNS depression can be increased when Reboxetine is combined with Gaboxadol. |
| Butabarbital | The risk or severity of CNS depression can be increased when Butabarbital is combined with Gaboxadol. |
| Butalbital | The risk or severity of CNS depression can be increased when Butalbital is combined with Gaboxadol. |
| Methysergide | The risk or severity of CNS depression can be increased when Methysergide is combined with Gaboxadol. |
| Cabergoline | The risk or severity of CNS depression can be increased when Cabergoline is combined with Gaboxadol. |
| Phenytoin | The risk or severity of CNS depression can be increased when Phenytoin is combined with Gaboxadol. |
| Topiramate | The risk or severity of CNS depression can be increased when Topiramate is combined with Gaboxadol. |
| Clemastine | The risk or severity of CNS depression can be increased when Clemastine is combined with Gaboxadol. |
| Venlafaxine | The risk or severity of CNS depression can be increased when Venlafaxine is combined with Gaboxadol. |
| Etomidate | The risk or severity of CNS depression can be increased when Etomidate is combined with Gaboxadol. |
| Morphine | The risk or severity of CNS depression can be increased when Morphine is combined with Gaboxadol. |
| Talbutal | The risk or severity of CNS depression can be increased when Talbutal is combined with Gaboxadol. |
| Pentobarbital | The risk or severity of CNS depression can be increased when Pentobarbital is combined with Gaboxadol. |
| Valproic acid | The risk or severity of CNS depression can be increased when Valproic acid is combined with Gaboxadol. |
| Zolmitriptan | The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Gaboxadol. |
| Codeine | The risk or severity of CNS depression can be increased when Codeine is combined with Gaboxadol. |
| Dihydroergotamine | The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Gaboxadol. |
| Tolcapone | The risk or severity of CNS depression can be increased when Tolcapone is combined with Gaboxadol. |
| Hydromorphone | The risk or severity of CNS depression can be increased when Hydromorphone is combined with Gaboxadol. |
| Olanzapine | The risk or severity of CNS depression can be increased when Olanzapine is combined with Gaboxadol. |
| Cetirizine | The risk or severity of CNS depression can be increased when Cetirizine is combined with Gaboxadol. |
| Protriptyline | The risk or severity of CNS depression can be increased when Protriptyline is combined with Gaboxadol. |
| Trimethadione | The risk or severity of CNS depression can be increased when Trimethadione is combined with Gaboxadol. |
| Clobazam | The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Gaboxadol. |
| Chlorzoxazone | The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Gaboxadol. |